OSL · ASX

OncoSil Medical Ltd (ASX:OSL)

AU$0.004

 0.0 (0.0%)
ASX:Live
08/05/2025 12:00:00 AM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

OSL Overview

OSL Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About OSL

Website

OncoSil Medical Ltd

Telephone

61.2.8935.9629

Address

Level 5 7 Eden Park Drive Macquarie Park, New South Wales (NSW) 2113

Description

OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. It engages in the development of novel and safer radiation therapy treatments. The company was founded by David McAuliffe on April 14, 2005 and is headquartered in North Sydney, Australia.

OSL Price Chart

Key Stats

Market Cap

AU$18.43M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.01

Trade Value (12mth)

AU$12,496.00

1 week

14.29%

1 month

0%

YTD

-42.86%

1 year

-11.11%

All time high

0.20

Key Fundamentals

EPS 3 yr Growth

-44.30%

EBITDA Margin

%

Operating Cashflow

-$11m

Free Cash Flow Return

-147.50%

ROIC

-162.30%

Interest Coverage

-3,293.30

Quick Ratio

3.30

Other Data

Shares on Issue (Fully Dilluted)

3975m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

OSL Announcements

Latest Announcements

Date Announcements

07 May 25

OncoSil Outperforms SBRT in Pancreatic Cancer Outcomes

×

OncoSil Outperforms SBRT in Pancreatic Cancer Outcomes

05 May 25

Application for quotation of securities - OSL

×

Application for quotation of securities - OSL

02 May 25

Quarterly Activities/Appendix 4C Cash Flow Report Addendum

×

Quarterly Activities/Appendix 4C Cash Flow Report Addendum

01 May 25

Consolidation/Split - OSL

×

Consolidation/Split - OSL

01 May 25

Update - Consolidation/Split - OSL

×

Update - Consolidation/Split - OSL

30 April 25

Notice of Extraordinary General Meeting/Proxy Form

×

Notice of Extraordinary General Meeting/Proxy Form

30 April 25

Tender Process for CRO to Undertake G-BA Study Commences

×

Tender Process for CRO to Undertake G-BA Study Commences

29 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

01 April 25

Appointment of Company Secretary

×

Appointment of Company Secretary

18 March 25

OncoSil appoints Ms Shelley Steyn as Chief Financial Officer

×

OncoSil appoints Ms Shelley Steyn as Chief Financial Officer

25 February 25

Appendix 4D and Half Year Accounts

×

Appendix 4D and Half Year Accounts

11 February 25

Investor Webinar Presentation

×

Investor Webinar Presentation

07 February 25

Investor Webinar 11 February 2025

×

Investor Webinar 11 February 2025

04 February 25

120 German Hospitals entitled to negotiate fee for OncoSil

×

120 German Hospitals entitled to negotiate fee for OncoSil

31 January 25

Response to Appendix 3X Query

×

Response to Appendix 3X Query

30 January 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 January 25

Initial Director's Interest Notice LS

×

Initial Director's Interest Notice LS

28 January 25

OncoSil Medical Receives MDR Approval

×

OncoSil Medical Receives MDR Approval

15 January 25

Lel Smits to be appointed Non-Executive Director

×

Lel Smits to be appointed Non-Executive Director

08 January 25

OncoSil receives $1.05m R&D tax incentive

×

OncoSil receives $1.05m R&D tax incentive

31 December 24

First Patient in Australia Randomised in TRIPP-FFX Trial

×

First Patient in Australia Randomised in TRIPP-FFX Trial

20 December 24

Change of Director's Interest Notice DC

×

Change of Director's Interest Notice DC

13 December 24

Oncosil completes $1 million Share Purchase Plan (SPP)

×

Oncosil completes $1 million Share Purchase Plan (SPP)

13 December 24

Application for quotation of securities - OSL

×

Application for quotation of securities - OSL

13 December 24

Application for quotation of securities - OSL

×

Application for quotation of securities - OSL

OSL Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -5.2 6.9 43.2 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 21.9 32.4 34.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -31.2 -83.9 -124.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.00 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.3 -45.3 -69.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 1,057 1,196 2,219 Lock Lock Lock
Basic m Lock Lock Lock Lock 1,057 1,196 2,219 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock 8.8 58.6 40.5 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 5 6 7 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -7 -6 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -8.0 3.5 11.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -2,902.2 -1,766.3 -1,108.5 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 3,002 1,866 1,208 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -11 -12 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.4 -9.7 -4.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -4,867.5 -3,366.4 -2,514.2 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -11 -13 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.9 -10.0 -3.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -4,922.3 -3,414.3 -2,522.7 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -12 -12 -13 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -1 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -11 -11 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock -2.8 -5.7 -5.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -4,627.8 -3,085.0 -2,306.0 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -10 -11 -11 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 9 9 6 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -10 -11 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -14.1 -12.4 3.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -43.6 -30.9 -21.3 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 11 9 5 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 13 11 7 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -11 -9 -4 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 11 10 5 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 11 10 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -6.0 -12.4 -51.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -82.1 -98.9 -177.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -96.1 -114.8 -251.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -96.5 -116.7 -175.4 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -92.0 -107.0 -162.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -86.7 -106.7 -147.5 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -574.9 -1,135.6 -3,293.3 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.0 0.7 0.3 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -98.3 -93.3 -93.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 7.2 7.2 3.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 7.2 7.2 3.3 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 88.5 83.6 71.1 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -571.9 -721.1 -556.9 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.2 0.3 0.4 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.1 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 401.7 261.1 217.5 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.1 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.1 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -4,986.6 -3,384.1 -2,509.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -88.4 -108.4 -192.9 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -82.1 -98.9 -177.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.2 1.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -96.1 -114.8 -251.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -96.1 -114.8 -251.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 1,644.9 1,088.7 961.3 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 1,644.9 1,088.7 961.3 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 56.6 50.3 60.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 1,588.3 1,038.4 900.4 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

OSL Shortsell

Frequently Asked Questions

The current share price of OncoSil Medical Ltd (OSL:ASX) is AU$0.004.
The 52-week high share price for OncoSil Medical Ltd (OSL:ASX) is AU$0.01.
The 52-week low share price for OncoSil Medical Ltd (OSL:ASX)? is AU$0.00.
OncoSil Medical Ltd (OSL:ASX) does not pay a dividend.
OncoSil Medical Ltd (OSL:ASX) does not pay a dividend.
OncoSil Medical Ltd (OSL:ASX) has a franking level of 0.0%.
OncoSil Medical Ltd (OSL:ASX) is classified in the Healthcare.
The current P/E ratio for OncoSil Medical Ltd (OSL:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.